Novartis Pharmaceuticals has a total of 206 patents globally, out of which 118 have been granted. Of these 206 patents, more than 29% patents are active. United States of America is where Novartis Pharmaceuticals has filed the maximum number of patents, followed by Germany and Italy. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Novartis Pharmaceuticals.
Novartis Pharmaceuticals is a sub part of Novartis was founded in the year 1996. Novartis Pharmaceuticals operates as a pharmaceutical company. The business conducts research, develops, produces, and markets patent-protected prescription medications for critical medical conditions including the heart, central nervous system, cancer, ophthalmology, organ transplantation, and respiratory systems.
Do read about some of the most popular patents of Novartis Pharmaceuticals which have been covered by us in this article and also you can find Novartis Pharmaceuticals patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Novartis Pharmaceuticals patent portfolio.
Keep track of every patent move and monitor competitor activity in real-time. Click here for full insights:
How many patents does Novartis Pharmaceuticals have?
Novartis Pharmaceuticals has a total of 206 patents globally. These patents belong to 90 unique patent families. Out of 206 patents, 61 patents are active.
How Many Patents did Novartis Pharmaceuticals File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Novartis Pharmaceuticals Applications Filed | Novartis Pharmaceuticals Patents Granted |
| 2026 | – | 1 |
| 2025 | 1 | 3 |
| 2024 | 2 | 1 |
| 2022 | 8 | 1 |
| 2021 | 4 | 3 |
| 2020 | 3 | 3 |
| 2019 | 13 | 2 |
| 2018 | 6 | 4 |
| 2017 | 1 | 3 |
| 2016 | 21 | 17 |
Which Novartis Pharmaceuticals Drug Patents are Expiring in the Next 10 Years?
The patent no. US7378423B2 which is expiring in May, 2027, describing cancer-fighting agent inhibiting cell growth in colorectal, pancreatic, lung, breast cancers, etc. Contains a pyrimidine compound that induces p15 and/or p27 proteins and/or inhibits MEK.
Given below is the list of few drugs patented by Novartis Pharmaceuticals accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Mekinist | US7378423B2 | Pyrimidine compound and medical… | May, 2027 |
| Xiidra | US8367701B2 | Crystalline pharmaceutical and meth… | Apr, 2029 |
| Promacta | US8052994B2 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1… | Feb, 2028 |
| Tafinlar | US10869869B2 | Method of adjuvant cancer treatment… | Aug, 2033 |
| Tasigna | US8293756B2 | Pharmaceutical compositions comp… | Sep, 2027 |
Interested in knowing about Novartis Drug Patents Expiring in the next 10 years?
How many Novartis Pharmaceuticals patents are Alive/Dead?
Worldwide Patents
How Many Patents did Novartis Pharmaceuticals File in Different Countries?
Countries in which Novartis Pharmaceuticals Filed Patents
| Country | Patents |
| United States of America | 153 |
| Germany | 10 |
| Italy | 9 |
| Spain | 8 |
| Europe (EPO) | 6 |
| United Kingdom | 6 |
| Estonia | 3 |
| Russia | 2 |
| Japan | 1 |
| Israel | 1 |
| Canada | 1 |
| Korea (South) | 1 |
| Australia | 1 |
| Hungary | 1 |
Where are the Research Centres of Novartis Pharmaceuticals Patents Located?
10 Best Novartis Pharmaceuticals Patents
US8415355B2 is the most popular patent in the Novartis Pharmaceuticals portfolio. It has received 162 citations so far from companies like Aduro Biotech, Teva Pharmaceuticals and Lupin Limited.
Below is the list of 10 most cited patents of Novartis Pharmaceuticals:
| Publication Number | Citation Count |
| US8415355B2 | 162 |
| US8685980B2 | 150 |
| US6887459B1 | 71 |
| US8961964B2 | 67 |
| US8877938B2 | 56 |
| US8324225B2 | 48 |
| US9220631B2 | 47 |
| US20100222334A1 | 41 |
| US20100305150A1 | 40 |
| US20100092541A1 | 37 |
How many inventions of other companies were rejected due to Novartis Pharmaceuticals patents?
The statistics below share strategic R&D insights. It tells the companies that were trying to protect inventions similar to Novartis Pharmaceuticals invention. They couldn’t because Novartis Pharmaceuticals had protected those before them.
Examiners at the USPTO referred 39 Novartis Pharmaceuticals patents in 147 rejections (35 USC § 102 or 35 USC § 103 types).
The top citing companies in the Novartis Pharmaceuticals patent portfolio are Nissan Chemical, Silvergate Pharmaceuticals, and Dupont.
List of the Companies whose Patents were rejected citing Novartis Pharmaceuticals –
| Company | Number of Patent Applications that faced Rejection Citing Novartis Pharmaceuticals Patents | Number of Rejections (102 & 103) |
| Nissan Chemical | 10 | 18 |
| Silvergate Pharmaceuticals | 5 | 5 |
| Dupont | 4 | 12 |
| Eci Pharmaceuticals | 3 | 5 |
| Astex | 3 | 4 |
| Supernus Pharmaceuticals | 3 | 6 |
| Rush University Medical Center | 2 | 6 |
| Crystal Pharmatech | 2 | 3 |
| National Jewish Health | 2 | 2 |
| Mankind Pharma | 2 | 4 |
Count of 102 and 103 Type Rejections based on Novartis Pharmaceuticals Patents
Top Novartis Pharmaceuticals Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US7371865B2 | 11 |
| US20100222334A1 | 9 |
| US8080562B2 | 5 |
| US9220631B2 | 5 |
| US7037525B2 | 4 |
| US6410329B1 | 4 |
| US8877938B2 | 2 |
| US8575146B2 | 2 |
| US8410131B2 | 2 |
| US20100233253A1 | 2 |
| US8685980B2 | 2 |
| US6537524B1 | 2 |
| US9045457B2 | 2 |
| US8119148B2 | 2 |
| US9708303B2 | 2 |
What Percentage of Novartis Pharmaceuticals US Patent Applications were Granted?
Novartis Pharmaceuticals (Excluding its subsidiaries) has filed 456 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 240 have been granted leading to a grant rate of 60.76%.
Below are the key stats of Novartis Pharmaceuticals patent prosecution at the USPTO.
Which Law Firms are managing US Patents for Novartis Pharmaceuticals?
| Law Firm | Total Applications | Success Rate |
| Novartis (Inhouse IP Dept.) | 327 | 76.32% |
| Troutman Pepper Hamilton Sanders Llp | 26 | 0.00% |
| Finnegan Henderson Farabow Garrett & Dunner | 15 | 23.81% |
| K&L Gates | 14 | 12.50% |
| Cooley Llp | 10 | 77.78% |
| Fish & Richardson Pc | 5 | 50.00% |
| Institute Of the Genomics | 4 | 33.33% |
| Gerald D Sharkin | 4 | 100.00% |
| Mccarter & English Llp | 4 | 25.00% |
| Morrison & Foerster Llp | 4 | 100.00% |
What are Novartis Pharmaceuticals key innovation segments?
What Technologies are Covered by Novartis Pharmaceuticals?
The chart below distributes patents filed by Novartis Pharmaceutical